Author

Kiyotoshi Kuramoto

Institution: Kissei Pharmaceutical (Japan)

Observed institution: Kissei Pharmaceutical (Japan)

ORCID: 0009-0004-6567-162X

Observed ORCID: 0009-0004-6567-162X

OpenAlex ID: A5060078980

Long‐term safety of desmopressin orally disintegrating tablets in men with nocturia due to nocturnal polyuria: Interim results of a specified drug use–results survey in Japan

2024 · Yoshimasa Ogawa, Shujiro Murata, et al. · LUTS Lower Urinary Tract Symptoms · 7

Real-world safety and efficacy of twice-daily budesonide 2-mg foam in patients with ulcerative colitis: interim analysis of post-marketing surveillance

2021 · Teppei Omori, Masayuki Saruta, et al. · Expert Opinion on Pharmacotherapy · 7

Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study

2019 · Hiroshi Takahashi, Shinichi Kubono, et al. · Drugs in R&D · 4

Long‐Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use‐Results Survey in Japan

2026 · Yoshimasa Ogawa, Kiyotoshi Kuramoto, et al. · LUTS Lower Urinary Tract Symptoms · 1

Safety and effectiveness of carotegrast methyl in patients with ulcerative colitis: an interim report of post-marketing surveillance in Japan

2026 · Masayuki Saruta, Yoshiharu Miura, et al. · Crohn s & Colitis 360

Safety and effectiveness of budesonide rectal foam for ulcerative colitis in a large-scale, multicenter, prospective observational study: final report of post-marketing surveillance in Japan

2026 · Masayuki Saruta, Teppei Omori, et al. · Intestinal Research

Works count: 6

Citation count: 19

H-index: 3

I10-index: